BOULDER, CO / ACCESSWIRE / April 9, 2024 / Sonoma Pharmaceuticals (Formerly Known As Oculus Innovative Sciences, Inc.), Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced the expansion of its Microcyn® Negative-Pressure Wound Therapy (NPWT) Solution products in the United States..

BOULDER，CO/ACCESSWIRE/2024年4月9日/Sonoma Pharmaceuticals（原名Oculus Innovative Sciences，Inc.）（纳斯达克：SNOA）是一家全球医疗保健领导者，开发和生产基于专利技术的稳定次氯酸（HOCl）产品，用于广泛的应用，包括伤口，眼睛，口腔和鼻腔护理，皮肤病，足病，动物保健和无毒消毒剂，今天宣布在美国扩展其Microcyn®负压伤口治疗（NPWT）解决方案产品。。

Microcyn Negative-Pressure Wound Therapy Solution, an innovation in advanced wound care, is now available in convenient sizes of 250mL, 450mL, and 990mL. Designed to meet the diverse needs of healthcare professionals and patients, Microcyn NPWT Solution is a cutting-edge solution that provides effective cleaning and irrigation for wounds with precision and reliability.

Microcyn负压伤口治疗解决方案是先进伤口护理的创新，现在可提供250mL，450mL和990mL的方便尺寸。Microcyn NPWT解决方案旨在满足医疗保健专业人员和患者的各种需求，是一种前沿解决方案，可精确可靠地为伤口提供有效的清洁和冲洗。

Microcyn NPWT Solution complements a wide array of negative-pressure therapies. Sonoma's solution delivers optimal wound cleansing and management, promoting faster healing and improved patient outcomes. It does not contain antibiotics, and as a result, it does not promote antibiotic resistance and helps reduce odor by removing necrotic tissue..

Microcyn NPWT解决方案补充了各种负压疗法。Sonoma的解决方案提供了最佳的伤口清洁和管理，促进了更快的愈合并改善了患者的预后。它不含抗生素，因此不会促进抗生素耐药性，并通过去除坏死组织来帮助减少气味。。

Sonoma will showcase this expanded product line at CPHI Japan in Tokyo April 17-19, 2024, at booth 5K-03. Sonoma will also showcase Microcyn NPWT Solution at the Symposium on Advanced Wound Care (SAWC) Spring Conference in Orlando, Florida, May 14-18, 2024 at booth 1102. To set up a meeting at either conference, please contact busdev@sonomapharma.com..

Sonoma将于2024年4月17日至19日在东京的CPHI日本展台5K-03展示这一扩展的产品线。索诺玛还将在2024年5月14日至18日于佛罗里达州奥兰多举行的高级伤口护理（SAWC）春季会议上，在1102号展位展示Microcyn NPWT解决方案。要在任一会议上安排会议，请联系busdev@sonomapharma.com..

'With a focus on quality, ease of use, and enhanced wound care, Sonoma Pharmaceuticals continues to lead the way in providing innovative solutions for the healthcare industry,' said Amy Trombly, CEO of Sonoma Pharmaceuticals. 'We are seeing increased demand for negative-pressure wound therapy solutions that offer improved efficacy and safety in wound cleansing, and we are pleased to respond to this unmet need by expanding our offerings of Microcyn technology in this important area of patient care.'.

Sonoma Pharmaceuticals首席执行官艾米·特罗姆布莱（AmyTrombly）说，Sonoma Pharmaceuticals专注于质量、易用性和增强伤口护理，在为医疗保健行业提供创新解决方案方面继续处于领先地位我们看到对负压伤口治疗解决方案的需求增加，这些解决方案在伤口清洁方面提供了改进的功效和安全性，我们很高兴通过在这一重要的患者护理领域扩大我们的微同步器技术产品来应对这一未得到满足的需求。”。

For more information, or to order Microcyn® Negative-Pressure Wound Therapy Solution, please visit https://pro.sonomapharma.com/ or contact our customer service department at 720-452-9690 or customerservice@sonomapharma.com.

欲了解更多信息，或订购Microcyn®负压伤口治疗溶液，请访问https://pro.sonomapharma.com/或致电720-452-9690联系我们的客户服务部或customerservice@sonomapharma.com.

About Sonoma Pharmaceuticals, Inc.

关于Sonoma Pharmaceuticals，Inc。

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue.

Sonoma Pharmaceuticals是开发和生产稳定次氯酸（HOCl）产品的全球医疗保健领导者，产品应用广泛，包括伤口，眼睛，口腔和鼻腔护理，皮肤病，足病，动物保健和无毒消毒剂。Sonoma的产品在临床上被证明可以安全地减少瘙痒、疼痛、疤痕和刺激，并且不会损害健康组织。

In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico.

HOCl的体外和临床研究表明，它可以安全地管理皮肤擦伤，撕裂伤，轻微刺激，伤口和完整的皮肤。索诺玛的产品直接或通过全球55个国家的合作伙伴销售，该公司积极寻求新的分销合作伙伴。该公司的总部位于科罗拉多州的博尔德，制造业务位于墨西哥的瓜达拉哈拉。

European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com..

欧洲营销和销售总部位于荷兰罗尔蒙德。有关更多信息，请访问www.sonomappharma.com。有关合作机会，请联系busdev@sonomapharma.com..

Forward-Looking Statements

前瞻性声明

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc.

除历史信息外，本新闻稿中所述事项在1995年《私人证券诉讼改革法案》的“安全港”规定范围内具有前瞻性，包括关于Sonoma Pharmaceuticals，Inc.商业和技术进步以及未来财务表现的声明。

and its subsidiaries (the 'company'). These forward-looking statements are identified by the use of words such as 'continue,' 'develop,' 'anticipate,' 'expect' and 'expand,' among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission.

及其子公司（“公司”）。这些前瞻性陈述通过使用诸如“继续”、“发展”、“预期”、“期望”和“扩展”等词语来识别。本新闻稿中的前瞻性陈述受到公司业务固有的某些风险和不确定性的影响，这些风险和不确定性可能会导致实际结果发生变化，包括监管临床和指南的发展可能会发生变化，科学数据可能不足以满足监管标准或收到所需的监管许可或批准，临床结果可能无法在实际患者环境中复制，公司专利和专利申请提供的保护可能会受到竞争对手的质疑，无效或规避，公司产品的可用市场将不会像预期的那样大，公司产品将无法渗透一个或多个目标市场，收入将不足以满足公司的现金需求，为进一步发展提供资金，以及与新型冠状病毒大流行和经济发展相关的不确定性，不同国家和城市的不同产品配方和多种不同的监管和营销要求，以及公司向证券交易委员会提交的文件中不时详述的其他风险。

The company disclaims any obligation to update these forward-looking statements, except as req.

公司不承担更新这些前瞻性声明的任何义务，除非有要求。

Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Sonoma Pharmaceuticals™和Microcyn®是Sonoma Pharmaceuticals，Inc.的商标或注册商标。所有其他商标和服务商标均为其各自所有者的财产。

SOURCE: Sonoma Pharmaceuticals, Inc.

资料来源：Sonoma Pharmaceuticals，Inc。

View the original press release on accesswire.com

在accesswire.com上查看原始新闻稿